French biotech Abivax has raised $800 million in an upsized Nasdaq share sale, giving it enough cash to fund operations through the second quarter of 2029. The move pushes the company's market value to nearly $11 billion and changes the dynamics around any potential takeover talks.
What Happened
Abivax originally planned to raise $600 million through the sale of American depositary shares (ADSs) on the Nasdaq. Strong investor demand allowed it to increase the offering to $800 million by selling 6.4 million ADSs at $125 each. Underwriters also have a 15% option that could push total proceeds to about $920 million.
The company said the funds will support preparations for a U.S. launch of its lead drug candidate, obefazimod, as well as additional clinical studies. Obefazimod is an oral pill being developed to treat chronic gut inflammation, including ulcerative colitis and Crohn's disease.
Why It Matters for Investors
In the biotech world, cash runway is a key factor in deal negotiations. When a company's funding is running low, potential acquirers can wait it out, knowing the company may be forced to accept a lower price or faster timeline. By extending its funding into 2029, Abivax removes that pressure.
“This shifts the company from needing a deal to choosing if and when,” the company indicated. The higher valuation also raises the price tag for any bidder. A near-$11 billion equity value, plus the extra shares issued, means a buyer would need to justify a larger cash-and-stock offer than it might have when the company was valued lower in mid-June.
For investors watching the sector, this is a reminder that big equity raises can be as much about negotiating power as they are about paying for trials. Similar dynamics have played out in other industries; for example, Lendlease raised AU$400 million by selling down its Kuala Lumpur project, using the proceeds to strengthen its balance sheet.
Background on Obefazimod
Abivax is developing obefazimod as a once-daily oral treatment for inflammatory bowel diseases (IBD), a market that includes blockbuster drugs like Humira and Entyvio. Late-stage inflammation drugs can turn into multibillion-dollar products, which is why big drugmakers have been watching Abivax closely.
However, talks have been slowed by questions about safety signals flagged after earlier Phase 3 results. Reuters reported that after Abivax shared additional Phase 3 maintenance data, demand for the share sale was strong enough to allow the upsizing.
The company now has the financial flexibility to advance its clinical program and prepare for a U.S. launch without the immediate need to strike a deal. That could be a positive signal for existing shareholders, as it reduces the risk of a distressed sale.
What to Watch Next
Investors will be watching for further Phase 3 data readouts, particularly on safety and efficacy. Any positive results could increase the company's bargaining power further. Conversely, negative data could reignite pressure to find a partner or buyer.
The broader market for biotech IPOs and follow-on offerings has been mixed. Recent deals like ITG's Nasdaq debut and Bending Spoons' IPO show that investor appetite for new issues varies by sector. Abivax's successful upsizing suggests that demand for high-potential biotech assets remains strong.
For everyday investors, the key takeaway is that Abivax has bought itself time and leverage. Whether that leads to a premium takeover or a successful standalone launch remains to be seen, but the company is now in a stronger position to dictate its own fate.
